Business Wire

ESI-GROUP

10.5.2021 18:02:14 CEST | Business Wire | Press release

Share
ESI Group Launches a “No Meeting Day” to Protect Its Employees Work-life Balance and Restore the Importance of Taking Time

ESI Group (Paris:ESI):

An unbalanced equation
A year ago, in the wake of COVID-19, companies began adapting to ensure the continuity of their activities during lockdown. With people bound to their homes, the opportunity to create social connections, in a professional or personal context, has strongly been affected. Indeed, as a major component of the life of many citizens, offices and workplaces are and remain a main outlet for socialization. In order to counterbalance this change, companies have utilized tools, like digital meetings, to continue connecting employees to maintain team spirit and a sense of belonging. Companies became one of the last remaining social links things when everything else was put on hold. As a result, teams’ agendas have filled up; meetings now punctuate the day, causing stress, taking away the time needed to perform various tasks and reducing focus time, pushing the workday into the evening or even the weekend.

Time to breathe and take a step back: “No meeting Wednesday”
To enhance the work-life balance and well-being of its employees, ESI Group, a leading innovator in virtual prototyping solutions and a global enabler of industrial transformation, has implemented a "No Meeting Wednesday": one day a week without meetings, allowing employees more flexibility in the organization of their work, pivoting from stressful days to focus and efficiency. Flexibility is key in the goal of this initiative: not in the day chosen – the same for all - but in its application. In fact, customer meetings, candidates’ interview or emergencies, can of course always be held. To be effective, this "No meeting Wednesday" has to be accepted by all teams and above all, accompanied by complementary managerial actions– sharing of good practices for productive and timely meetings: shortened time with clear and shared objectives, etc.

"The pandemic has not only disrupted work habits but also the entire life of our teams. Our role, as a company, is to provide them with the most serene environment possible so that they can fulfill their work while maintaining a work-life balance. Widespread home office has a significant impact on our professional ultra-connection and generates an intensive use of video-conference meetings. Based on this situation, we have set up this day without meetings every week. Reestablish meetings best practices goes hand in hand with it. With this initiative, we want above all to continue to preserve our teams while knowing that the time saved will be a time of focus, restoring the importance of taking time, oriented toward efficiency" declares Yannick Charron, Director of Human Resources, France and Headquarter, ESI Group.

" I believe that, despite the difficulties we have to overcome throughout the pandemic, we, as a company, have the opportunity to reinvent ourselves and evolve by being adaptive. We have created a motto to get us through this ordeal and turn it into an opportunity: "Stay in touch - Be agile - Transform". Our group is evolving and transforming in line with our strategy and our corporate objectives, but also and above all because all our teams are encouraged to leave their comfort zone, to take risks and to reinvent themselves. We need to create time in the diaries to allow for a breath of fresh air, which is necessary for everyone's balance, but also for this state of mind", explains Cristel de Rouvray, CEO ESI Group.

About ESI Group
Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval, energy and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information, go to www.esi-group.com .

Follow ESI

http://www.esi-group.com/linkedin
http://www.esi-group.com/facebook
http://www.esi-group.com/twitter
http://www.esi-group.com/youtube

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye